<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We have studied the clinical effect of lomefloxacin (LFLX) for the documented <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infections</z:e> in the patients with <z:e sem="disease" ids="C0947743,C0018939" disease_type="Disease or Syndrome" abbrv="">hematological disorders</z:e>, and also analyzed the prophylactic usefulness of LFLX for the prevention of succeeding <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e> after the chemotherapy </plain></SENT>
<SENT sid="1" pm="."><plain>Fifty five patients were entered in the trial, and 51 patients were eligible </plain></SENT>
<SENT sid="2" pm="."><plain>Among 51 eligible patients, 40 patients were suffered from accompanied <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infections</z:e>, and 11 patients were registered for the prophylaxis of the <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>In the group of documented <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e>, the ratio of out-patients was 62.5%, and 63.0% in prophylactic usage </plain></SENT>
<SENT sid="4" pm="."><plain>In the treatment of the documented <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e>, LFLX was effective in 20 patients; the efficacy rate was 50.0% </plain></SENT>
<SENT sid="5" pm="."><plain>In the prophylactic administration, LFLX was effective in 9 patients, yielded the efficacy rate of 81.8% </plain></SENT>
<SENT sid="6" pm="."><plain>LFLX was effective for <z:hpo ids='HP_0000001'>all</z:hpo> 5 patients with <z:hpo ids='HP_0000010'>urinary tract infection</z:hpo>, in 10 out of 18 patients with <z:hpo ids='HP_0011947'>respiratory tract infection</z:hpo> (efficacy rate; 55.6%), in 5 out of 12 patients with <z:hpo ids='HP_0001945'>fever</z:hpo> from undetermined origin (41.7%), showed no effect for <z:hpo ids='HP_0001082'>cholecystitis</z:hpo>, <z:hpo ids='HP_0002583'>colitis</z:hpo>, and phlegmon </plain></SENT>
<SENT sid="7" pm="."><plain>Bacteriological examinations revealed that <z:hpo ids='HP_0000001'>all</z:hpo> of the bacteria detected as pathogens were eradicated </plain></SENT>
<SENT sid="8" pm="."><plain>The efficacy rate in the group of the malignant disorders such as <z:hpo ids='HP_0001909'>leukemia</z:hpo>/ <z:hpo ids='HP_0002665'>lymphoma</z:hpo> was smaller than that of non-tumorigenic diseases as <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> </plain></SENT>
<SENT sid="9" pm="."><plain>As <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>), four <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e>-bearing patients and five patients with prophylactic usage were analyzed </plain></SENT>
<SENT sid="10" pm="."><plain>The efficacy rate of LFLX was 50.0 and 80.0%, respectively, and the overall efficacy rate was 66.7% </plain></SENT>
<SENT sid="11" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients without prophylactic administration failed to have <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infections</z:e> </plain></SENT>
<SENT sid="12" pm="."><plain>Thus, LFLX was thought to be useful in the prevention of succeeding <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infections</z:e> after the chemotherapy </plain></SENT>
<SENT sid="13" pm="."><plain>No clinical and laboratory adverse reactions were reported </plain></SENT>
</text></document>